Atlas Trials

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Clinical trial NCT01147536 · TERMINATED

Trial details

NCT number
NCT01147536
Sponsor
Agenus Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2010-01-01
Primary completion
2012-06-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.